In oncology drug development, biomarker-driven studies are pivotal, enabling the selection of patient populations most likely to benefit from specific therapeutic interventions. These studies have ...
Comparable efficacy of venetoclax 50mg with posaconazole versus venetoclax 400mg in newly diagnosed AML patients: A prospective study of pharmacokinetics, toxicity, and clinical outcomes. Detection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results